Canada markets open in 6 hours 23 minutes

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9900-0.0200 (-1.00%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.0100
Open2.0000
Bid0.0000 x 1100
Ask0.0000 x 1100
Day's Range1.9819 - 2.0300
52 Week Range1.9819 - 5.3900
Volume84,925
Avg. Volume305,493
Market Cap28.477M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-1.2440
Earnings DateFeb. 28, 2022 - Mar. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

    NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acer’s recent corporate developments. “This quarter was all about preparing regulatory filings to advance our pipeline pr

  • GlobeNewswire

    Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

    Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new U.S. patent to Acer for certain claims related to ACER-001 (sodium phenylbutyrate). Patent 11

  • Simply Wall St.

    Acer Therapeutics Inc. (NASDAQ:ACER): Are Analysts Optimistic?

    Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...